Login to Your Account



'Scar' tactics: Onlookers weigh phase III data in IPF from Intermune, BI

By Randy Osborne
Staff Writer

Monday, May 19, 2014

The implausibility of comparing data with would-be competitors from separate trials did not stop industry wizards from following their 'Inpulsis' and guessing anyway, with the upshot that overall chances seemed to ASCEND for Intermune Inc.'s Esbriet in IPF, over Boehringer Ingelheim GmbH's phase III outcomes with the tyrosine kinase inhibitor nintedanib.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription